Comparing GETINGE AB/ADR (OTCMKTS:GNGBY) and Echo Therapeutics (OTCMKTS:ECTE)

Share on StockTwits

GETINGE AB/ADR (OTCMKTS:GNGBY) and Echo Therapeutics (OTCMKTS:ECTE) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, analyst recommendations, valuation, institutional ownership, dividends, earnings and risk.

Analyst Ratings

This is a breakdown of current ratings and target prices for GETINGE AB/ADR and Echo Therapeutics, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
GETINGE AB/ADR 0 0 0 0 N/A
Echo Therapeutics 0 0 0 0 N/A

Volatility and Risk

GETINGE AB/ADR has a beta of 1.82, indicating that its stock price is 82% more volatile than the S&P 500. Comparatively, Echo Therapeutics has a beta of 9.94, indicating that its stock price is 894% more volatile than the S&P 500.

Institutional & Insider Ownership

0.0% of GETINGE AB/ADR shares are held by institutional investors. 7.0% of Echo Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Profitability

This table compares GETINGE AB/ADR and Echo Therapeutics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
GETINGE AB/ADR -2.41% 8.50% 3.81%
Echo Therapeutics N/A N/A N/A

Valuation & Earnings

This table compares GETINGE AB/ADR and Echo Therapeutics’ revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
GETINGE AB/ADR $2.67 billion 1.65 -$111.30 million N/A N/A
Echo Therapeutics N/A N/A N/A N/A N/A

Echo Therapeutics has lower revenue, but higher earnings than GETINGE AB/ADR.

Dividends

GETINGE AB/ADR pays an annual dividend of $0.07 per share and has a dividend yield of 0.4%. Echo Therapeutics does not pay a dividend.

Summary

GETINGE AB/ADR beats Echo Therapeutics on 5 of the 8 factors compared between the two stocks.

GETINGE AB/ADR Company Profile

Getinge AB provides products and solutions for operating rooms, intensive-care units, sterilization departments, and life science companies and institutions. The company operates through Acute Care Therapies, Surgical Workflows, and Life Science segments. It offers practice-oriented monitoring systems and disposables; anesthesia, beating heart surgery, and ceiling devices; washer-disinfectors, consumables, and IT-solutions; connected solutions; consumables products; drain products; endoscope reprocessing; endoscopic vessel harvesting systems; extracorporeal life support or extracorporeal membrane oxygenation products; inspection and packaging services; intra-aortic balloon counter pulsation therapies; critical care ventilators; modular room systems; operating lights; operating tables and accessories; operating room (OR) furniture; OR integration systems; patient flow management solutions; patient transport solutions; sealing equipment; sterile supply management and traceability solutions; sterilizers; surgical assist systems; surgical perfusion components; loading and distribution trolleys; trays and baskets; and after sales consulting services. The company also provides automated bedding handling equipment, closure processing systems, washers, and isolation and sterile transfer products; professional financial advisory services to hospitals and medical facilities; and education and training services. It offers its products through a network of proprietary sales companies, as well as through agents and distributors in Europe, the Middle East, Africa, the Americas, Asia, and Pacific. The company has a strategic partnership with Verb Surgical Inc. to develop digital surgery solutions. Getinge AB was founded in 1904 and is headquartered in Gothenburg, Sweden.

Echo Therapeutics Company Profile

Echo Therapeutics, Inc. engages in the development of transdermal skin permeation and diagnostic medical devices for wearable-health consumer and diabetes outpatient markets. It is developing continuous glucose monitoring (CGM) system, a needle-free wireless continuous glucose monitoring system in a hospital setting in the European Union. The company has a licensing agreement with Ferndale Pharma Group, Inc. to develop, manufacture, distribute, and market devices for skin preparation prior to the application of topical anesthetics or analgesics prior to a range of needle-based medical procedures in North America, the United Kingdom, South America, Australia, New Zealand, Switzerland, and other portions of the European Community. In addition, it has a license agreement with Handok Pharmaceuticals Co., Ltd. to develop, use, market, import, and sell CGM to medical facilities and individual consumers in South Korea; and a license, development, and commercialization agreement with Medical Technologies Innovation Asia, Ltd to research, develop, manufacture, and use CGM in the People's Republic of China, Hong Kong, Macau, and Taiwan. The company was founded in 1989 and is headquartered in Iselin, New Jersey.

Receive News & Ratings for GETINGE AB/ADR Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GETINGE AB/ADR and related companies with MarketBeat.com's FREE daily email newsletter.